Abstract
Introduction

46
There is strength in diversity. Diversity in scientific research includes the perspectives and creative ideas that are harnessed, the model systems and experimental tools employed, the 48 types of investigators supported, and the regions in which research is conducted. Multiple 49 levels of diversity increase the likelihood of scientific breakthroughs and maximize the return on 50 taxpayers' investments in federally sponsored research (Lorsch, 2015; Peifer, 2017a ).
51
Unfortunately, there are barriers to maximizing diversity.
53
A landmark study in Science reported that black investigators are much less likely to get their 54 National Institutes of Health (NIH) research grant applications funded than white applicants, 55 even after for controlling for other factors (Ginther et al., 2011) . There are also large differences 56 in success rates for investigators grouped by age (Levitt & Levitt, 2017 
65
One way to visualize the distribution of wealth, the magnitude of disparity and the degree of 
70
display the fraction of funding that is allocated to a given bin and all higher-funded bins (i.e.,
71
those to its left). For example, the first two bins of investigators (the top-funded 3.8%) received
72
22% of all research dollars. Strikingly, the distributions of research dollars among institutions 73 and states (Wahls, 2016 (Wahls, , 2018 are even more heavily skewed than that for investigators 74 (Basson et al., 2016; Collins, 2017) . Half of all NIH research project grant dollars go to about
75
19% of funded investigators, 2% of funded institutions and 10% of states (Figure 1) . The actual 76 magnitude of disparity is even higher than depicted here because many well-qualified scientists 77 who apply for support go unfunded. About three-quarters of applicants are denied funding each 78 year (Rockey, 2014) and less than one in three applicants get any of their research project grant 79 applications funded over a five-year period (Lauer, 2016c) .
81
This "funding inequality has been rising since 1985, with a small segment of investigators and 82 institutes getting an increasing proportion of funds, and investigators who start in the top funding 83 ranks tend to stay there" (Katz & Matter, 2017) . While the rich get richer, there is increasing 84 hyper-competition elsewhere in the ranks for the remaining funds. This creates a barrier for the 85 entry of talented young scientists into the biomedical workforce, threatening the future of the 86 research enterprise (Carr, 2013) . Similarly, the approximately 70% of awardees who hold a 87 single NIH grant are at increased risk of losing that support, their research laboratories, and 88 even their livelihood (Peifer, 2017a 
94
Among all types of disparities in allocations of NIH funding described to date, one is 95 preeminent-and poorly defined as to its causes and consequences. The fact that the NIH
96
gives the majority of its extramural research project grant dollars to tiny minority (about 2%) of 97 funded organizations (Figure 1) 
107
To gain insight into potential causes of the funding disparities, funding and productivity metrics 108 were analyzed, encompassing data over a ten-year period, for fifteen institutions whose 
118
The first two variables examined have to do with likelihood of funding. The application-level 119 success rate is essentially the fraction of applications that get funded in a given fiscal year, 120 although revised applications in the same fiscal year are not counted in the denominator 121 (Rockey, 2014) . The investigator-level funding rate is the fraction of applicants that get one or 122 more of their applications funded in a given fiscal year (Rockey, 2014 
128
( Figure 2A) . As a group, investigators at the prestigious institutions were, on average, 1.7-129 times more likely to get each grant application funded than those at the less-prestigious 130 institutions (33.9% vs 20.5%, p < 0.001). Similarly, the investigator funding rate of each 131 prestigious institution exceeded that of each less-prestigious institution, and investigators at the 132 prestigious institutions were, on average, 1.7-times more likely to get at least one application 133 funded each year that they applied (37.6% vs 22.4%, p = 0.003) ( Figure 2B ).
135
The next two variables examined have to do with amounts of funding. A search of the NIH 
152
The placement of institutions into prestigious and less-prestigious groups was part of the 153 experimental plan, which was laid out before any data were acquired, and the assignments 
160
versus the total amounts of funding to each organization.
162
The conclusions are straightforward. Differences in grant application success rates, investigator 
169
Consequences of these imbalances are documented in subsequent sections of the Results and 170 are described in the Discussion.
172
Less-prestigious institutions produce greater returns on investments
174
The disparities in allocations of funding by the NIH might be justified if the prestigious 
191
To gain insight into this possibility, the relative citation ratio (RCR) ( 
214
It should be emphasized that the differences in productivity do not necessarily mean that
215
investigators at the less-prestigious institutions are "better scientists" or are "more meritorious" 
226
substantially less money per award (e.g., Figure 2D ). Moreover, there can be substantial 227 differences in productivity between groups (e.g., Figure 2E-2F) , which is germane to whether 228 differences in success rates and award sizes are warranted. These various factors can be 229 evaluated simultaneously by using the SR/P value, which is success rate divided by 230 productivity. Differences in SR/P values for investigators grouped in any way that is desired
231
(e.g., by race, gender, age, institution or state) and using any measure of productivity that is 232 desired (e.g., publication rate or citation impact per unit of funding), reveal the success rate- 
236
6 For all four of the different ways that the data were analyzed, the SR/P value (and a related 237 metric, below) of each prestigious institution exceeded that of each less-prestigious institution
238
( Figure 2G-2H and Supplementary Table S1 ). When publications were used as the basis for 239 productivity, the mean SR/P value of the prestigious institutions was 2.6-fold higher than that for Table S1 ). The fact that four distinct approaches yielded
245
concordant results (mean of 2.41 ± 0.27 standard deviation) suggests that SR/P and FR/P 246 metrics developed for this study provide robust measures for the magnitude of disparity.
248
Inverse correlations between amounts of funding and productivity
250
To gain insight into consequences of the funding disparities, publication-based and citation 
262
Generalizability of the findings
264
The analyses encompassed institutions whose amounts of funding ranged from $3 million to
265
$440 million per year and the conclusions are based on statistically significant differences in 266 data from more than 100,000 research project grant applications, 40,000 awards, and 95,000 
277
Discussion
279
There are three key findings described in this study. First, allocations of NIH research project 280 grant funding to institutions are extremely skewed, favoring a tiny minority and disfavoring the 281 vast majority (Figure 1) . Second, differences in grant application success rates and award 282 sizes contribute to these disparities (Figure 2A, 2D) . The impacts of differences in success 
290
Funding allocations are biased by institution
292
The extreme disparities in NIH funding to institutions (e.g., 1% of funded organizations get about
293
34% of the dollars), which favor a tiny minority and disfavor the vast majority (Figure 1) 
321
We are hard-wired, biologically, to make conscious and subconscious distinctions between 322 groups of people and those distinctions, however unjustified they might be, can affect 323 allocations of funding.
325
A little bias goes a long way. Even small differences in reviewers' scores for preferred and non-326 preferred applicants produce large differences in grant application success rates (Day, 2015) .
327
There are at least four distinct steps of the funding process, involving both scientific merit review
328
(peer review) and administrative funding decisions, at which bias can occur (Figure 4) .
329
Consequently, the effects of even minor, subconscious biases at each step can multiply Table S1 ) for the magnitude of disparity between the groups of prestigious 335 and less-prestigious institutions analyzed (mean of 2.41 ± 0.27 standard deviation). The SR/P 336 metric thus provides a potentially useful benchmark for ameliorating disparities and, as 337 described below, for optimizing the efficiency with which research dollars are expended.
339
Disparities in funding affect the return on taxpayers' investments
341
The principle that unbalanced allocations of grant funding yield diminishing marginal returns
342
(incremental output for each additional dollar of funding) has been documented extensively at 
361
This study revealed that diminishing marginal returns also apply at the level of institutions returns (e.g., Figure 3 ) and, furthermore, must do so in proportion to their variable magnitude.
383
Overall, the process would have to strike a balance between three fundamental needs: First,
384
ensure that investigators at-large are allowed to compete on equal footing for grants and grant 385 dollars. Second, accommodate the possibility that some groups of investigators might be of 386 greater value to the research enterprise than other groups. Third, maximize the net return on 387 taxpayers' investments. The SR/P metrics developed for this study provide a straightforward
388
and impartial way to satisfy, simultaneously, these three fundamental needs.
390
The differences in SR/P values between institutions (Figure 2G-2H 
415
Methods
417
Data sets
419
Data on funding and productivity by institution for FY2006 to FY2015 are provided in Table S1 .
439
Statistical tests
441
Grouped data sets were analyzed using the Mann Whitney test; continuous variable data sets
442
were analyzed using linear least squares regression; analyses were conducted in Prism
443
(GraphPad Software, Inc., La Jolla, CA, USA).
445
Data availability
447
All relevant data are contained in the manuscript and its Supplementary Information file.
448
Additional datasets (e.g., raw results from searches of NIH RePORTER and PubMed) are 
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